Using a Transformative Human-Centered Design Approach to Co-Create Communication Materials for the Alimatravir Efficacy Trial, EXPrESSIVE-11

Using a Transformative Human-Centered Design Approach to Co-Create Communication Materials for the Alimatravir Efficacy Trial, EXPrESSIVE-11

Merck’s EXPrESSIVE program is investigating the efficacy of alimatravir (AMI) for monthly oral PrEP. With support from the Gates Foundation, AVAC works to ensure there is strong, consistent engagement with community representatives to influence the design and implementation of the trials, with an eye toward future rollout and access planning for AMI. Leveraging AVAC’s expertise […]